Diabetes patients soon may have alternatives to needles in the way they receive insulin as companies have both pulmonary and oral formulations in the clinic. But rather than competing in the marketplace, these formulations may find separate niches, with oral used to increase baseline insulin levels and pulmonary drug used for rapid acting, pre-meal insulin.

In Phase II data reported at